Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according to a study.
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
Obesity affects both physical and mental health, leading to body-image issues and emotional eating. Dr. Nand Kumar of AIIMS ...
Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...
While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Bicycling on MSN14h
New Report Challenges Current Definition of ObesityOne of the inadequacies of using body mass index (BMI) as a predictive factor is that “current BMI-based measures of obesity can both underestimate and overestimate” a persons ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback